262 related articles for article (PubMed ID: 29016943)
1. Radiologic progression of glioblastoma under therapy-an exploratory analysis of AVAglio.
Nowosielski M; Ellingson BM; Chinot OL; Garcia J; Revil C; Radbruch A; Nishikawa R; Mason WP; Henriksson R; Saran F; Kickingereder P; Platten M; Sandmann T; Abrey LE; Cloughesy TF; Bendszus M; Wick W
Neuro Oncol; 2018 Mar; 20(4):557-566. PubMed ID: 29016943
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma.
Wick W; Chinot OL; Bendszus M; Mason W; Henriksson R; Saran F; Nishikawa R; Revil C; Kerloeguen Y; Cloughesy T
Neuro Oncol; 2016 Oct; 18(10):1434-41. PubMed ID: 27515827
[TBL] [Abstract][Full Text] [Related]
3. Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma.
Nowosielski M; Wiestler B; Goebel G; Hutterer M; Schlemmer HP; Stockhammer G; Wick W; Bendszus M; Radbruch A
Neurology; 2014 May; 82(19):1684-92. PubMed ID: 24727314
[TBL] [Abstract][Full Text] [Related]
4. Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo.
Ellingson BM; Abrey LE; Garcia J; Chinot O; Wick W; Saran F; Nishikawa R; Henriksson R; Mason WP; Harris RJ; Leu K; Woodworth DC; Mehta A; Raymond C; Chakhoyan A; Pope WB; Cloughesy TF
Neuro Oncol; 2018 Oct; 20(11):1525-1535. PubMed ID: 29897562
[TBL] [Abstract][Full Text] [Related]
5. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O
Cloughesy T; Finocchiaro G; Belda-Iniesta C; Recht L; Brandes AA; Pineda E; Mikkelsen T; Chinot OL; Balana C; Macdonald DR; Westphal M; Hopkins K; Weller M; Bais C; Sandmann T; Bruey JM; Koeppen H; Liu B; Verret W; Phan SC; Shames DS
J Clin Oncol; 2017 Jan; 35(3):343-351. PubMed ID: 27918718
[TBL] [Abstract][Full Text] [Related]
6. Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma.
Ellingson BM; Abrey LE; Nelson SJ; Kaufmann TJ; Garcia J; Chinot O; Saran F; Nishikawa R; Henriksson R; Mason WP; Wick W; Butowski N; Ligon KL; Gerstner ER; Colman H; de Groot J; Chang S; Mellinghoff I; Young RJ; Alexander BM; Colen R; Taylor JW; Arrillaga-Romany I; Mehta A; Huang RY; Pope WB; Reardon D; Batchelor T; Prados M; Galanis E; Wen PY; Cloughesy TF
Neuro Oncol; 2018 Aug; 20(9):1240-1250. PubMed ID: 29660006
[TBL] [Abstract][Full Text] [Related]
7. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
[TBL] [Abstract][Full Text] [Related]
8. Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma.
Schäfer N; Proescholdt M; Steinbach JP; Weyerbrock A; Hau P; Grauer O; Goldbrunner R; Friedrich F; Rohde V; Ringel F; Schlegel U; Sabel M; Ronellenfitsch MW; Uhl M; Grau S; Hänel M; Schnell O; Krex D; Vajkoczy P; Tabatabai G; Mack F; Schaub C; Tzaridis T; Nießen M; Kebir S; Leutgeb B; Urbach H; Belka C; Stummer W; Glas M; Herrlinger U
Neuro Oncol; 2018 Jun; 20(7):975-985. PubMed ID: 29121274
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial.
Balana C; De Las Penas R; Sepúlveda JM; Gil-Gil MJ; Luque R; Gallego O; Carrato C; Sanz C; Reynes G; Herrero A; Ramirez JL; Pérez-Segura P; Berrocal A; Vieitez JM; Garcia A; Vazquez-Estevez S; Peralta S; Fernandez I; Henriquez I; Martinez-Garcia M; De la Cruz JJ; Capellades J; Giner P; Villà S
J Neurooncol; 2016 May; 127(3):569-79. PubMed ID: 26847813
[TBL] [Abstract][Full Text] [Related]
10. Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial.
Kebir S; Schaub C; Junold N; Hattingen E; Schäfer N; Steinbach JP; Weyerbrock A; Hau P; Goldbrunner R; Galldiks N; Weller J; Mack F; Tzaridis T; Bähr O; Seidel C; Schlegel U; Schmidt-Graf F; Rohde V; Borchers C; Tabatabai G; Hänel M; Sabel M; Gerlach R; Krex D; Belka C; Vatter H; Proescholdt M; Glas M; Herrlinger U
J Neurooncol; 2019 Sep; 144(3):501-509. PubMed ID: 31325144
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma.
Sepúlveda JM; Belda-Iniesta C; Gil-Gil M; Pérez-Segura P; Berrocal A; Reynés G; Gallego O; Capellades J; Ordoñez JM; La Orden B; Balañá C
Clin Transl Oncol; 2015 Sep; 17(9):743-50. PubMed ID: 26033428
[TBL] [Abstract][Full Text] [Related]
12. Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial.
Schaub C; Kebir S; Junold N; Hattingen E; Schäfer N; Steinbach JP; Weyerbrock A; Hau P; Goldbrunner R; Niessen M; Mack F; Stuplich M; Tzaridis T; Bähr O; Kortmann RD; Schlegel U; Schmidt-Graf F; Rohde V; Braun C; Hänel M; Sabel M; Gerlach R; Krex D; Belka C; Vatter H; Proescholdt M; Herrlinger U; Glas M
J Cancer Res Clin Oncol; 2018 Aug; 144(8):1581-1589. PubMed ID: 29808316
[TBL] [Abstract][Full Text] [Related]
13. Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials.
Carlson JA; Reddy K; Gaspar LE; Ney D; Kavanagh BD; Damek D; Lillehei K; Chen C
J Neurooncol; 2015 Jun; 123(2):251-7. PubMed ID: 25920710
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686.
Boxerman JL; Zhang Z; Safriel Y; Rogg JM; Wolf RL; Mohan S; Marques H; Sorensen AG; Gilbert MR; Barboriak DP
Neuro Oncol; 2018 Sep; 20(10):1400-1410. PubMed ID: 29590461
[TBL] [Abstract][Full Text] [Related]
15. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.
Lechapt-Zalcman E; Levallet G; Dugué AE; Vital A; Diebold MD; Menei P; Colin P; Peruzzy P; Emery E; Bernaudin M; Chapon F; Guillamo JS
Cancer; 2012 Sep; 118(18):4545-54. PubMed ID: 22359215
[TBL] [Abstract][Full Text] [Related]
16. Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group database.
Blumenthal DT; Won M; Mehta MP; Gilbert MR; Brown PD; Bokstein F; Brachman DG; Werner-Wasik M; Hunter GK; Valeinis E; Hopkins K; Souhami L; Howard SP; Lieberman FS; Shrieve DC; Wendland MM; Robinson CG; Zhang P; Corn BW
Neuro Oncol; 2018 Jun; 20(7):966-974. PubMed ID: 29462493
[TBL] [Abstract][Full Text] [Related]
17. MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma.
Kim BS; Kong DS; Seol HJ; Nam DH; Lee JI
J Neurooncol; 2017 Jul; 133(3):615-622. PubMed ID: 28536992
[TBL] [Abstract][Full Text] [Related]
18. Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study.
Boxerman JL; Zhang Z; Safriel Y; Larvie M; Snyder BS; Jain R; Chi TL; Sorensen AG; Gilbert MR; Barboriak DP
Neuro Oncol; 2013 Jul; 15(7):945-54. PubMed ID: 23788270
[TBL] [Abstract][Full Text] [Related]
19. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.
Stupp R; Hegi ME; Neyns B; Goldbrunner R; Schlegel U; Clement PM; Grabenbauer GG; Ochsenbein AF; Simon M; Dietrich PY; Pietsch T; Hicking C; Tonn JC; Diserens AC; Pica A; Hermisson M; Krueger S; Picard M; Weller M
J Clin Oncol; 2010 Jun; 28(16):2712-8. PubMed ID: 20439646
[TBL] [Abstract][Full Text] [Related]
20. Radiographic patterns of progression with associated outcomes after bevacizumab therapy in glioblastoma patients.
Cachia D; Elshafeey NA; Kamiya-Matsuoka C; Hatami M; Alfaro-Munoz KD; Mandel JJ; Colen R; DeGroot JF
J Neurooncol; 2017 Oct; 135(1):75-81. PubMed ID: 28702781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
